gene

MMP9

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MMP9: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1794Connections

2Hypotheses

7Analyses

50Outgoing

50Incoming

0Experiments

17Debates

Summary

MMP9 is a gene implicated in neurodegeneration research. Key relationships include: activates, therapeutic target, associated with. Associated with ALI, ALS, AMI. Connected to 884 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	MMP9
Chromosome	20q12-13
Protein Family	Matrix metalloproteinase family ( gelatinase B)
Protein Type	Protease
Target Class	Protease
Function	Small molecule zinc-chelating inhibitors or antibody-based inhibition
Mechanism of Action	Small molecule zinc-chelating inhibitors or antibody-based inhibition
Primary Expression	Secreted, extracellular space, neutrophil granules
Druggability	Medium (0.54)
Clinical Stage	Phase III
Molecular Weight	92 kDa (pro-MMP9), 82 kDa (active)
Amino Acids	20 aa
Pathways	Akt, Apoptosis, Autophagy, Blood-Brain Barrier, Cell Cycle
UniProt ID	P14780
GeneCards	MMP9
Human Protein Atlas	MMP9
Associated Diseases	acute-on-chronic liver failure, Aging, ALI, Als, Alzheimer
Known Drugs/Compounds	Andrographis paniculata, curcumin, CURCUMIN, doxycycline, Genistein, GENISTEIN
Interactions	ABCD1, ABCD2, ADAM15, ADAMTS1, AEP, AGING
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Matrix Metalloproteinase-9-Mediated Claudin-5 Clea Gut dysbiosis-driven monocyte reprogramming toward
KG Connections	1793 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🧬 3D Structure Comparison — MMP9 Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

1GKC — X-ray / Cryo-EM

🔮 AI Predicted Structure

P14780 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (3)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

flowchart TD
    MMP9(["MMP9"])
    Inflammation["Inflammation"]
    Als["Als"]
    Aging["Aging"]
    Coronary_Artery_Disease["Coronary Artery Disease"]
    Luteolin["Luteolin"]
    neutrophil_extracellular_traps("neutrophil extracellular traps")
    necroptosis("necroptosis")
    autophagy("autophagy")
    h_1acdd55e["h-1acdd55e"]
    MMP9_IN_1{"MMP9-IN-1"}
    GATA4(["GATA4"])
    Akt_Mtor["Akt/Mtor"]
    Mapk["Mapk"]

    MMP9 -->|"therapeutic target"| Inflammation
    MMP9 -->|"activates"| Als
    MMP9 -->|"therapeutic target"| Als
    MMP9 -->|"therapeutic target"| Aging
    MMP9 -->|"biomarker for"| Coronary_Artery_Disease
    Luteolin -.->|"downregulates"| MMP9
    MMP9 -->|"participates in"| neutrophil_extracellular_traps
    MMP9 -->|"associated with"| necroptosis
    MMP9 -.->|"inhibits"| autophagy
    h_1acdd55e -->|"therapeutic target"| MMP9
    MMP9_IN_1 -.->|"inhibits"| MMP9
    GATA4 -.->|"inhibits"| MMP9
    Akt_Mtor -->|"upregulates"| MMP9
    h_1acdd55e -->|"targets gene"| MMP9
    MMP9 -->|"therapeutic target"| Mapk

    style MMP9 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (1116)

Target	Relation	Type	Str
MMP9	encodes	protein	0.00
Inflammation	therapeutic_target	disease	1.00
Als	activates	disease	0.95
Als	therapeutic_target	disease	0.95
Coronary Artery Disease	biomarker_for	disease	0.95
Aging	therapeutic_target	disease	0.95
extracellular matrix degradation	mediates	process	0.95
neutrophil extracellular traps	participates_in	phenotype	0.90
necroptosis	associated_with	phenotype	0.90
autophagy	inhibits	phenotype	0.90
glycocalyx	degrades	process	0.90
cell migration	promotes	process	0.90
AKT	therapeutic_target	gene	0.90
Autophagy	activates	pathway	0.90
Mapk	therapeutic_target	pathway	0.90
Breast Cancer	biomarker_for	disease	0.85
Cancer	activates	disease	0.85
Cancer	inhibits	disease	0.85
Inflammation	activates	disease	0.85
Cancer	therapeutic_target	disease	0.85
Bone Loss	involved_in	phenotype	0.85
Cell Migration	promotes	process	0.85
Cell Metastasis	involved_in	process	0.85
vascular barrier integrity	suppresses	phenotype	0.85
Blood-Brain Barrier Integrity	associated_with	phenotype	0.85
Brain Edema	associated_with	phenotype	0.85
acute-on-chronic liver failure	associated_with	disease	0.80
Blood-Brain Barrier Function	associated_with	process	0.80
AQP4	inhibits	protein	0.80
mortality	contributes_to	phenotype	0.80
Non-Small-Cell Lung Cancer	involved_in	disease	0.80
Type 2 Diabetes Mellitus	biomarker_for	disease	0.80
neural stem cells	interacts_with	cell_type	0.80
neural stem cells	regulates	cell_type	0.80
Apoptosis	activates	pathway	0.80
extracellular matrix	remodels	structure	0.80
CANCER	activates	gene	0.80
Metastasis	therapeutic_target	pathway	0.80
NLRP3	activates	protein	0.80
AUTOPHAGY	activates	gene	0.80
INFLAMMATION	therapeutic_target	gene	0.80
APOPTOSIS	activates	gene	0.80
CANCER	inhibits	gene	0.80
Tumor	inhibits	disease	0.75
Cardiovascular	therapeutic_target	disease	0.75
Neurodegeneration	activates	disease	0.75
Hepatocellular Carcinoma	therapeutic_target	disease	0.75
Breast Cancer	inhibits	disease	0.75
Carcinoma	therapeutic_target	disease	0.75
Fibrosis	biomarker_for	disease	0.75

Incoming (678)

Source	Relation	Type	Str
MMP9	encodes	gene	0.00
H6	suppresses	hypothesis	0.00
genes-mmp9	documents	wiki	1.00
Luteolin	downregulates	compound	0.95
HB147	downregulates	compound	0.90
GATA4	inhibits	protein	0.90
Hu-Loaded Exosomes	downregulates	compound	0.90
h-1acdd55e	targets	hypothesis	0.90
Akt/Mtor	upregulates	pathway	0.90
MMP9-IN-1	inhibits	drug	0.90
MMP2	associated_with	gene	0.90
Timp-1	inhibits	protein	0.90
Litebamine	downregulates	compound	0.90
genes-mmp9	describes	wiki	0.90
GENES	therapeutic_target	gene	0.90
TNF	therapeutic_target	gene	0.90
H3K56Ac	regulates	biomarker	0.85
NFKB1	upregulates	protein	0.85
Genistein	binds	compound	0.85
AKT/MTOR Signaling Pathway	upregulates	pathway	0.85
cardamom nanoemulsion	downregulates	compound	0.85
H3K27Ac	regulates	biomarker	0.85
IL1B	upregulates	protein	0.85
CURCUMIN	targets	drug	0.85
FB23	downregulates	drug	0.85
IL-6	associated_with	gene	0.82
TNF	upregulates	pathway	0.80
NDRG2	upregulates	gene	0.80
C9ORF72	upregulates	gene	0.80
p65	activates	protein	0.80
Andrographis paniculata	inhibits	drug	0.80
Qingqi Liangying formula	downregulates	drug	0.80
UVB	contributes_to	drug	0.80
INFLAMMATION	activates	gene	0.80
IL-6	interacts_with	protein	0.80
PI3K	therapeutic_target	gene	0.80
GENES	associated_with	gene	0.80
AKT1	targets	gene	0.80
MMP2	inhibits	gene	0.80
TNF	associated_with	gene	0.74
IL-1B	associated_with	gene	0.74
OSTEOCLASTS	expressed_in	cell_type	0.72
STAT3	regulates	protein	0.72
IRN	inhibits	drug	0.72
MMP9_IN1	inhibits	drug	0.72
LUTEOLIN	regulates	drug	0.72
MMP2	biomarker_for	gene	0.70
GABAERGIC	transports	cell_type	0.70
MICROGLIA	markers	cell_type	0.70
IGF1	associated_with	gene	0.70

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Matrix Metalloproteinase-9-Mediated Claudin-5 Cleavage Drive	0.515	-	What blood-brain barrier permeability ch
Gut dysbiosis-driven monocyte reprogramming toward NETotic p	0.380	Alzheimer's disease	Systemic immune profiling and peripheral

Mentioning Analyses (7)

Scientific analyses that reference this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (17)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning MMP9 in their description or question text

No additional research found

MMP9

Understanding Entity Pages

Summary

Wiki Pages (3)

MMP9 Protein

MMP9 Protein

MMP9 Gene

Pathway Diagram

Outgoing (1116)

Incoming (678)

Targeting Hypotheses (2)

Mentioning Analyses (7)

What is the minimum effective dose of trazodone required for disease-modifying e

What blood-brain barrier permeability changes serve as early biomarkers for neur

What are the mechanisms by which microglial senescence contributes to ALS pathol

Blood-brain barrier tight junction disruption by neuroinflammatory cytokines

Can circadian interventions reverse microglial priming independent of sleep disr

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

Senolytic therapy for age-related neurodegeneration

Experiments (0)

Related Papers (0)

Debates (17)

Debate: LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Primin

Debate: ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE P

Debate: LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability i

Debate: TBK1 Loss Locks Microglia in an Aged/Senescent Transcriptional State, Fu

Debate: ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes

Should '40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Sele

Should 'ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matt

Hypothesis debate: SASP-Mediated Complement Cascade Amplification

Investigate how microglial senescence drives ALS progression through inflammatio

What is the minimum effective dose of trazodone required for disease-modifying e

Related Research